P. Mommen

发表

Prognostic factors for patients with small cell lung carcinoma

V. Ninane, M. Paesmans, J. Sculier, 2000, Cancer.

A three-arm phase III randomised trial comparing combinations of platinum derivatives, ifosfamide and/or gemcitabine in stage IV non-small-cell lung cancer.

J. Lafitte, V. Ninane, M. Paesmans, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase III randomised study comparing two different dose-intensity regimens as induction chemotherapy followed by thoracic irradiation in patients with advanced locoregional non-small-cell lung cancer.

J. Lafitte, V. Ninane, P. van Houtte, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Evaluation of the TN sub-staging in patients with initially unresectable stage III non-small cell lung cancer treated by induction chemotherapy. The European Lung Cancer Working Party.

J. Lafitte, V. Ninane, P. van Houtte, 1998, Lung cancer.

A three-arm phase III randomised trial assessing, in patients with extensive-disease small-cell lung cancer, accelerated chemotherapy with support of haematological growth factor or oral antibiotics

J. Lafitte, V. Ninane, M. Paesmans, 2001, British Journal of Cancer.

A phase II randomised trial comparing the cisplatin-etoposide combination chemotherapy with or without carboplatin as second-line therapy for small-cell lung cancer.

J. Lafitte, V. Ninane, M. Paesmans, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized trial comparing induction chemotherapy versus induction chemotherapy followed by maintenance chemotherapy in small-cell lung cancer. European Lung Cancer Working Party.

M. Paesmans, J. Sculier, J. Klastersky, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Original article: A randomized study comparing etoposide and vindesine with or without cisplatin as induction therapy for small cell lung cancer

M. Paesmans, J. Sculier, J. Klastersky, 1990 .

A phase II trial testing gemcitabine as second-line chemotherapy for non small cell lung cancer

J. Lafitte, V. Ninane, M. Paesmans, 2000 .

Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party.

M Paesmans, J P Sculier, M. Paesmans, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer

J. Lafitte, V. Ninane, M. Paesmans, 2000, British Journal of Cancer.

A randomised phase III trial comparing consolidation treatment with further chemotherapy to chest irradiation in patients with initially unresectable locoregional non-small-cell lung cancer responding to induction chemotherapy. European Lung Cancer Working Party.

J. Lafitte, V. Ninane, P. van Houtte, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Response to chemotherapy has predictive value for further survival of patients with advanced non-small cell lung cancer: 10 years experience of the European Lung Cancer Working Party.

M Paesmans, J P Sculier, M. Paesmans, 1997, European journal of cancer.

Induction chemotherapy with ifosfamide, etoposide, and anthracycline for small cell lung cancer: experience of the European Lung Cancer Working Party.

J. Sculier, J. Thiriaux, G. Bureau, 1995, Seminars in oncology.

Placebo controlled pneumococcal immunization in patients with bronchogenic carcinoma.

A. Safary, J. Klastersky, P. Mommen, 1986, European journal of cancer & clinical oncology.

A four-drug combination chemotherapy with cisplatin, mitomycin, vindesine and 5 fluorouracile: a regimen associated with major toxicity in patients with advanced non-small cell lung cancer

M. Paesmans, J. Sculier, F. Ries, 1994 .

Intensive Multiple Drug Induction Chemotherapy for Small-Cell Lung Cancer

J. Sculier, F. Ries, J. Klastersky, 1990 .

161 Carboplatin prescribed in mg/m2 in patients with advanced non small cell lung cancer (NSCLC): Is there an impact of the reached area under the curve (AUC) on response, survival and hematological toxicity?

J. Lafitte, V. Ninane, M. Paesmans, 1997 .

Evaluation of squamous cell carcinoma antigen as a new marker for lung cancer

M. Paesmans, J. Sculier, J. Body, 1990, Cancer.

A preliminary evaluation of calcitonin and PDN-21 as tumor markers for lung cancer. EORTC Lung Cancer Working Party.

J. Sculier, J. Body, J. Dumon, 1989, Henry Ford Hospital medical journal.

Subrenal capsule assay of fresh human tumors: problems and pitfalls.

P. Semal, J. Abrams, P. Dumont, 1986, European journal of cancer & clinical oncology.

A Pilot Study on a Muramyltripeptide Lipophilic Derivative Entrapped into Liposomes (CGP 19835A Lipid) in Patients with Advanced Non-Small-Cell Lung Cancer

M. Paesmans, J. Sculier, J. Body, 1993 .

Phase III randomized trial comparing cisplatin and carboplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer. European Lung Cancer Working Party.

J. Lafitte, V. Ninane, M. Paesmans, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic factors for response to chemotherapy containing platinum derivatives in patients with unresectable non-small cell lung cancer. (NSCLC).

M. Paesmans, J. Sculier, J. Klastersky, 1996, Lung cancer.

Long-term survival after chemotherapy containing platinum derivatives in patients with advanced unresectable non-small cell lung cancer

M. Paesmans, J. Sculier, J. Klastersky, 1994 .

A randomized study comparing etoposide and vindesine with or without cisplatin as induction therapy for small cell lung cancer

M. Paesmans, J. Sculier, J. Klastersky, 1990 .

Combination Chemotherapy with Ifosfamide and Nimustine (IMA) as Salvage Treatment for Small Cell Lung Cancer

M. Paesmans, J. Sculier, J. Klastersky, 1993 .

A three-arm phase III randomised trial testing accelerated chemotherapy with GM-CSF or cotrimoxazole in extensive disease smal-cell lung cancer

J. Lafitte, M. Paesmans, J. Sculier, 2001 .

Induction chemotherapy with cisplatin, etoposide and vindesine before radiation therapy for nonsmall-cell lung cancer. A randomized study.

P. van Houtte, J. Sculier, J. Klastersky, 1988, Antibiotics and chemotherapy.

Cisplatin-carboplatin-gemcitabine or ifosfamide-gemcitabine in advanced non-small cell lung carcinoma: two pilot studies.

T. Berghmans, J. Sculier, J. Klastersky, 1999, Anticancer Research.

A comparison of methods of calculation for estimating carboplatin AUC with a retrospective pharmacokinetic-pharmacodynamic analysis in patients with advanced non-small cell lung cancer. European Lung Cancer Working Party.

J. Lafitte, V. Ninane, M. Paesmans, 1999, European journal of cancer.

A phase II study testing paclitaxel as second-line single agent treatment for patients with advanced non-small cell lung cancer failing after a first-line chemotherapy.

J. Lafitte, V. Ninane, M. Paesmans, 2002, Lung cancer.

A four-drug combination chemotherapy with cisplatin, mitomycin, vindesine and 5 fluorouracile: a regimen associated with major toxicity in patients with advanced non-small cell lung cancer.

M. Paesmans, J. Sculier, F. Ries, 1994, Lung cancer.

Combination Chemotherapy with Ifosfamide and Nimustine (IMA) as Salvage Treatment for Small Cell Lung Cancer

M. Paesmans, J. Sculier, J. Klastersky, 1993 .

A phase II study evaluating the cisplatin and epirubicin combination in patients with unresectable malignant pleural mesothelioma.

J. Lafitte, M. Paesmans, T. Berghmans, 2005, Lung cancer.

Combination chemotherapy with mitomycin and vindesine in advanced non-small cell lung cancer: a pilot study by the Lung Cancer Working Party (Belgium).

P. Rocmans, J. Sculier, J. Klastersky, 1986, Cancer treatment reports.